ProStrakan signs research deal with Novartis; eyeing move to US market
Specialty pharma company ProStrakan Group PLC has signed a research deal with Novartis AG to develop antibody-based treatments for bone diseases.
(December 6, 2006)
Cytopia in $274m tie to Novartis DRUG developer Cytopia has signed a license and research deal with global pharmaceutical group Novartis potentially worth more than $274 million, the biggest license agreement by an Australian biotech firm.
(June 6, 2006)
Strategic Alliance with Infinity to discover drugs targeting Bcl-2 Novartis and Infinity Pharmaceuticals have entered into a strategic alliance to discover drugs targeting Bcl-2 protein family members for the treatment of a broad range of cancer indications.
(March 7, 2006)
Collaboration with SGX Pharmaceuticals to develop BCR-ABL inhibitors Novartis and SGX Pharmaceuticals, Inc announced that they have entered into a license and collaboration agreement focused on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant Chronic Myelogenous Leukemia (CML).
(March 28, 2006)
Novartis and Alnylam announce new collaboration to develop RNAi therapeutics for pandemic flu Novartis and Alnylam Pharmaceuticals, Inc. announced today the formation of a new collaboration to develop therapeutics for pandemic flu based on RNA interference (RNAi).
